How to manage patients with corticosteroids in oncology in the era of immunotherapy?
Mihaela Aldea(Institut Gustave Roussy), Jean‐Marie Michot(Institut Gustave Roussy), Émeline Orillard(Inserm), Olivier Lambotte(Inserm), Laura Mansi(Inserm), Florian Scotté(Université Paris-Saclay), Aurélien Marabelle(Institut Gustave Roussy)
Cited by 87
Related Papers
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
|The Lancet Oncology|2018|614
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
|Nature Reviews Clinical Oncology|2021|469
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
|Nature Medicine|2021|367
Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up
|Annals of Oncology|2020|319
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
|Cell Research|2019|246